<DOC>
	<DOCNO>NCT00495586</DOCNO>
	<brief_summary>The purpose study determine effectiveness antibiotic therapy patient acute exacerbation mild-to-moderate chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Effectiveness Antibiotic Therapy Exacerbations Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Antibiotics usually prescribe acute exacerbation chronic obstructive pulmonary disease ( COPD ) even though benefit mild-to-moderate COPD demonstrate . The aim study ass effectiveness antibiotic therapy exacerbation COPD , clinical variable associate improved clinical response antibiotic therapy respect placebo identify patient might recover acute exacerbation without antibiotic therapy . Methodology : prospective , randomise , double blind , placebo-controlled clinical trial , exacerbation ( least one criterion present : increase dyspnoea , increase sputum production and/or increase purulence ) patient older 40 yr. , smoker ex-smokers 10 pack-years , COPD FEV1 great 50 % , diagnose spirometry predict ratio FEV1/FVC &lt; 0.7 % . Exclusion criterion : severe COPD ( FEV1 &lt; 50 % ) , active neoplasm , tracheotomy , pneumonia , hospitalization criterion , patient previously antibiotic , immunodepressed , history hypersensitivity beta-lactams intolerance clavulanate , enrollment clinical trial , patient refuse take part study , patient spirometry test past two year . Sample size : 677 patient . Interventions : first visit : patient give detail clinical trial ask sign informed consent ; data : sputum color , chest X-ray ordered rule pneumonia , C-reactive protein level , peak flow measurement . The patient randomise receive amoxicillin plus clavulanate placebo schedule return 2nd follow-up visit 3 4 day assess clinical response peak flow measurement rule worsen condition . Third visit : schedule 9-11 day assess clinical response , drug-compliance peak flow measurement . Fourth visit 15-20 day clinical assessment observe whether relapse occur . Date follow exacerbation record .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Acute exacerbation ( least one criterion present : increase dyspnoea , increase sputum production and/or increase purulence ) patient older 40 year old , smokers exsmokers 10 packyears , COPD FEV1 great 50 % , diagnose spirometry predict ratio FEV1/FVC &lt; 0.7 % . Severe COPD ( FEV1 &lt; 50 % ) Pneumonia Active neoplasm Tracheotomy Criteria hospitalisation Patients previously antibiotic Immunodepressed patient History hypersensitivity betalactams intolerance clavulanate Enrollment clinical trial Patients refuse take part study Patients spirometry test past two year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Antibiotics</keyword>
</DOC>